Pfizer COVID-19 Vaccine Receives FDA Full Approval

The U.S. Food and Drug Administration (FDA) today granted full approval to the Pfizer-BioNTech COVID-19 Vaccine.

According to the FDA’s announcement, the vaccine will “now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.”

Today’s approval means that this vaccine meets the highest safety and efficacy standards and is a big step in the fight against COVID-19.

Other COVID-19 Updates

AHCA/NCAL Urges Biden Administration to Consider Implications of Vaccination Policy: Following an announcement from President Biden last week that all nursing home staff will be required to be fully vaccinated against COVID-19 in a forthcoming regulation, the nursing home industry warned about the potential impact on the profession’s already challenging workforce situation. Read More

COVID-19 Vaccine – Boosters vs. Additional Doses for Immunocompromised: HHS announced a plan to deliver booster shots for individuals who have been vaccinated with the Pfizer or Moderna COVID-19 vaccine. This comes following an announcement by the FDA and the CDC’s Advisory Committee on Immunization Practices to allow for the use of an additional dose of the Pfizer or Moderna vaccine in certain immunocompromised individuals. Read More

Pfizer COVID-19 Vaccine Receives FDA Full Approval

Stay Connected!

In this Issue...

Education & Events

References & Resources